Cargando…

HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine

The vaccines designed against the SARS-CoV-2 coronavirus are based on the spike (S) protein. Processing of the S protein by antigen-presenting cells (APC) and its subsequent presentation to T cells is an essential part of the development of a humoral response. HLA-class II alleles are considered imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutiérrez-Bautista, Juan Francisco, Sampedro, Antonio, Gómez-Vicente, Esther, Rodríguez-Granger, Javier, Reguera, Juan Antonio, Cobo, Fernando, Ruiz-Cabello, Francisco, López-Nevot, Miguel Ángel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949280/
https://www.ncbi.nlm.nih.gov/pubmed/35335034
http://dx.doi.org/10.3390/vaccines10030402
_version_ 1784674857532784640
author Gutiérrez-Bautista, Juan Francisco
Sampedro, Antonio
Gómez-Vicente, Esther
Rodríguez-Granger, Javier
Reguera, Juan Antonio
Cobo, Fernando
Ruiz-Cabello, Francisco
López-Nevot, Miguel Ángel
author_facet Gutiérrez-Bautista, Juan Francisco
Sampedro, Antonio
Gómez-Vicente, Esther
Rodríguez-Granger, Javier
Reguera, Juan Antonio
Cobo, Fernando
Ruiz-Cabello, Francisco
López-Nevot, Miguel Ángel
author_sort Gutiérrez-Bautista, Juan Francisco
collection PubMed
description The vaccines designed against the SARS-CoV-2 coronavirus are based on the spike (S) protein. Processing of the S protein by antigen-presenting cells (APC) and its subsequent presentation to T cells is an essential part of the development of a humoral response. HLA-class II alleles are considered immune response genes because their codified molecules, expressed on the surface of APCs (macrophages, dendritic, and B cells) present antigenic peptides to T cell via their T cell receptor (TCR). The HLA-class II genes are highly polymorphic, regulating what specific peptides induce follicular helper T cells (TFH) and promote B lymphocyte differentiation into plasma or memory B cells. This work hypothesizes that the presence of certain HLA-class II alleles could be associated with the intensity of the humoral response (amount, length) to the SARS-CoV2 mRNA 1273 vaccine. We have studied the relationship between the HLA-class II typing of 87 health workers and the level of antibodies produced 30 days after vaccination. We show a possible association between the HLA-DRB1* 07:01 allele and the HLA-DRB1*07:01~DQA1*02:01~DQB1*02:02 haplotype to a higher production of antibodies 30 days after the administration of the second dose of mRNA-1273.
format Online
Article
Text
id pubmed-8949280
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89492802022-03-26 HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine Gutiérrez-Bautista, Juan Francisco Sampedro, Antonio Gómez-Vicente, Esther Rodríguez-Granger, Javier Reguera, Juan Antonio Cobo, Fernando Ruiz-Cabello, Francisco López-Nevot, Miguel Ángel Vaccines (Basel) Article The vaccines designed against the SARS-CoV-2 coronavirus are based on the spike (S) protein. Processing of the S protein by antigen-presenting cells (APC) and its subsequent presentation to T cells is an essential part of the development of a humoral response. HLA-class II alleles are considered immune response genes because their codified molecules, expressed on the surface of APCs (macrophages, dendritic, and B cells) present antigenic peptides to T cell via their T cell receptor (TCR). The HLA-class II genes are highly polymorphic, regulating what specific peptides induce follicular helper T cells (TFH) and promote B lymphocyte differentiation into plasma or memory B cells. This work hypothesizes that the presence of certain HLA-class II alleles could be associated with the intensity of the humoral response (amount, length) to the SARS-CoV2 mRNA 1273 vaccine. We have studied the relationship between the HLA-class II typing of 87 health workers and the level of antibodies produced 30 days after vaccination. We show a possible association between the HLA-DRB1* 07:01 allele and the HLA-DRB1*07:01~DQA1*02:01~DQB1*02:02 haplotype to a higher production of antibodies 30 days after the administration of the second dose of mRNA-1273. MDPI 2022-03-06 /pmc/articles/PMC8949280/ /pubmed/35335034 http://dx.doi.org/10.3390/vaccines10030402 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gutiérrez-Bautista, Juan Francisco
Sampedro, Antonio
Gómez-Vicente, Esther
Rodríguez-Granger, Javier
Reguera, Juan Antonio
Cobo, Fernando
Ruiz-Cabello, Francisco
López-Nevot, Miguel Ángel
HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine
title HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine
title_full HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine
title_fullStr HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine
title_full_unstemmed HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine
title_short HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine
title_sort hla class ii polymorphism and humoral immunity induced by the sars-cov-2 mrna-1273 vaccine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949280/
https://www.ncbi.nlm.nih.gov/pubmed/35335034
http://dx.doi.org/10.3390/vaccines10030402
work_keys_str_mv AT gutierrezbautistajuanfrancisco hlaclassiipolymorphismandhumoralimmunityinducedbythesarscov2mrna1273vaccine
AT sampedroantonio hlaclassiipolymorphismandhumoralimmunityinducedbythesarscov2mrna1273vaccine
AT gomezvicenteesther hlaclassiipolymorphismandhumoralimmunityinducedbythesarscov2mrna1273vaccine
AT rodriguezgrangerjavier hlaclassiipolymorphismandhumoralimmunityinducedbythesarscov2mrna1273vaccine
AT reguerajuanantonio hlaclassiipolymorphismandhumoralimmunityinducedbythesarscov2mrna1273vaccine
AT cobofernando hlaclassiipolymorphismandhumoralimmunityinducedbythesarscov2mrna1273vaccine
AT ruizcabellofrancisco hlaclassiipolymorphismandhumoralimmunityinducedbythesarscov2mrna1273vaccine
AT lopeznevotmiguelangel hlaclassiipolymorphismandhumoralimmunityinducedbythesarscov2mrna1273vaccine